- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV6 vector system (AAV6 expression system, AAV6 packaging plasmid system, T cell validated ) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi (GM) AAV6 Vector system is including: 1) AAV6 Rep-Cap plasmid (AAV6-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).
You can produce AAV6 particle in 293T cell line in high titer using GeneMedi's AAV6 Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV6 vector has been validated in neuron(CNS),lung,liver,heart and muscle,with potential applications in tissue-specific gene therapy.AAV6 has also been proved a high transduction efficency in T cell,wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T(TCR-T) cell therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.
Go to AAV
vector system
>>Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-PK08 | AAV6 Vector System (Amp resistance) 1. AAV6 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 2028 | ||
| P-PK08 | AAV6 Vector System (Amp resistance) 1. AAV6 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-PK08 | AAV6 Vector System (Amp resistance) 1. AAV6 Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK08 | AAV6 Vector System (Amp resistance) 1. AAV6 Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK08-Kan | AAV6 Vector System (Kan resistance) 1. AAV6 Rep-Cap Plasmid (Kan resistance) , ≥10mg 2. AAV Helper Plasmid (Kan resistance) , ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-RC08 | AAV6 Rep-Cap
Plasmid (Amp resistance)
Size：5ug |
Academic | 935 | ||
| P-RC08 | AAV6 Rep-Cap
Plasmid (Amp resistance)
Size：5ug | Industry R&D (excluding CRO&CDMO&CXO) |
|||
| P-RC08 | AAV6 Rep-Cap
Plasmid (Amp resistance)
Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC08 | AAV6 Rep-Cap
Plasmid (Amp resistance)
Size：≥10mg |
All | |||
| P-RC08-Kan | AAV6 Rep-Cap
Plasmid(Kan resistance)
Size：≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| LECT2, a Ligand for Tie1, Plays a Crucial Role in Liver Fibrogenesis | CELL | 2019/8/29 |
| Lineage-specific regulatory changes in hypertrophic cardiomyopathy unraveled by single-nucleus RNA-seq and spatial transcriptomics | Cell Discovery | 2023/1/17 |
| FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System | Circulation | 2024/2/16 |
| Satellite‐based On‐orbit Printing of 3d Tumor Models | Advanced Materials | 2023/12/25 |
| CD1d protects against hepatocyte apoptosis in non?alcoholic steatohepatitis | Journal of Hepatology | 2023/10/28 |
| Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal | Cell Stem Cell | 2022/9/1 |
| TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis | Gastroenterology | 2019/12/28 |
| Manipulating bioactivities of endothelial progenitor cell-derived exosomes for promoting angiogenesis in ischemic vascular diseases | Nano Today | 2023/1/13 |
| Significance of m6A regulation in environmental health and safety (EHS) assessment: MWCNTs induced pulmonary toxicity through m6A modifications of mitophagy-related genes | Nano Today | 2022/9/21 |
| Cold-activated brown fat-derived extracellular vesicle-miR-378a-3p stimulates hepatic gluconeogenesis in male mice | Nature Communications | 2023/9/6 |
Validation data
Figure. Selected transduction results of AAV in vitro (in 293T cell line)
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
